- Development: New product development suites inclusive of expanded powder-in-capsule / powder-in-bottle micro-dosing capacity for early-phase studies
- Manufacturing: New manufacturing suites for tablet, multiparticulate and powder encapsulated drug products, with containment capability for highly potent compounds
- Packaging: New packaging suites fully equipped for compliant serialization
Quote from Dr. Christian Dowdeswell, VP & Head of Dosage Forms & Delivery Systems, Lonza Pharma & Biotech:
“Our Tampa site has an excellent track record of meeting the expedited timelines increasingly required in product development, and this investment allows us to further meet this challenge. The site has also had several successful domestic and international pre-approval inspections and our expansion allows us to fully support the commercialization of these new products.”
Quote from Anthony Macci, SVP Global Operations, Chemical Division, Lonza Pharma & Biotech:
“This expansion at our Tampa site adds concept-to-commercial capacity for the US market. We continue to invest heavily in our site network to ensure that flexible, phase-appropriate and integrated capabilities are in place to meet the needs of today's pharma and biotech innovator companies.”
Basel, Switzerland, 9 July 2019 – Lonza today announced the completion of a $15M multi-phase expansion of its solid oral dose development and manufacturing capabilities and capacity at its Tampa, FL (USA) site. The expansion will enable the Tampa site to provide more integrated services for customers across early-stage product development, clinical trial material manufacture and commercialization of innovative drug products. The Tampa site is part of Lonza's global network for the design, development and manufacturing of drug substances and intermediates, particle engineering / bioavailability enhancement and drug products for oral and inhaled applications.
As part of the multi-year investment, the site now boasts a new fully equipped Product Development & QC Laboratory area with 13 processing suites and two new packaging suites that can support commercial packaging, including low-humidity environments and serialization for complete tracking and tracing of commercial products. Lonza also added new manufacturing suites and dedicated sampling and dispensing areas capable of handling highly potent compounds.
In addition, Lonza expanded and renovated the cGMP Manufacturing Cleanroom facility, as well as completely renovating 25,000 sq ft of the existing cGMP OSD Manufacturing Cleanroom Facility.
The expansion included encapsulation and micro-dosing capabilities for Xcelodose® Precision Powder Micro-Dosing Technology, Glatt GPCG-10 fluid bed processing and Harro Hoefliger Modu-C capsule filling.